PAVmed Company Equity Multiplier from 2010 to 2025

PAVMZ Stock  USD 0.01  0.0001  1.01%   
PAVmed Series Company Equity Multiplier yearly trend continues to be fairly stable with very little volatility. Company Equity Multiplier is likely to outpace its year average in 2025. During the period from 2010 to 2025, PAVmed Series Company Equity Multiplier regression line of annual values had r-squared of  0.03 and arithmetic mean of  0.16. View All Fundamentals
 
Company Equity Multiplier  
First Reported
2010-12-31
Previous Quarter
(0.71)
Current Value
(0.67)
Quarterly Volatility
3.43425639
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check PAVmed Series financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PAVmed Series' main balance sheet or income statement drivers, such as Interest Expense of 1.2 M, Selling General Administrative of 37.4 M or Other Operating Expenses of 86 M, as well as many indicators such as Price To Sales Ratio of 13.27, Dividend Yield of 3.0E-4 or Days Sales Outstanding of 14.05. PAVmed financial statements analysis is a perfect complement when working with PAVmed Series Valuation or Volatility modules.
  
Check out the analysis of PAVmed Series Correlation against competitors.

Latest PAVmed Series' Company Equity Multiplier Growth Pattern

Below is the plot of the Company Equity Multiplier of PAVmed Series Z over the last few years. It is PAVmed Series' Company Equity Multiplier historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PAVmed Series' overall financial position and show how it may be relating to other accounts over time.
Company Equity Multiplier10 Years Trend
Pretty Stable
   Company Equity Multiplier   
       Timeline  

PAVmed Company Equity Multiplier Regression Statistics

Arithmetic Mean0.16
Geometric Mean1.50
Coefficient Of Variation2,101
Mean Deviation2.22
Median1.06
Standard Deviation3.43
Sample Variance11.79
Range16.0073
R-Value(0.17)
Mean Square Error12.28
R-Squared0.03
Significance0.53
Slope(0.12)
Total Sum of Squares176.91

PAVmed Company Equity Multiplier History

2025 -0.67
2024 -0.71
2023 -0.62
2022 -5.58
2021 1.41
2020 10.43
2019 -1.89

About PAVmed Series Financial Statements

PAVmed Series investors use historical fundamental indicators, such as PAVmed Series' Company Equity Multiplier, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in PAVmed Series. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Company Equity Multiplier(0.71)(0.67)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.